Related Experiment Video
Updated: Apr 6, 2026
09:14
Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
Published on: September 28, 2022
4.8K
Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis
Chen-Ge Song1, Jia-Jia Huang1, Ya-Jun Li2
1Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.
Plos One
|July 30, 2015
Summary
Elderly patients with Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) show poorer outcomes. This rare condition is linked to aggressive disease and significantly reduced survival rates compared to EBV-negative DLBCL.
Area of Science:
- Oncology
- Virology
- Hematology
Background:
- Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) is rarely reported in elderly individuals.
- Understanding the clinical characteristics and prognosis of this specific patient subgroup is crucial.
Purpose of the Study:
- To investigate the clinical features of EBV-positive DLBCL in patients over 50 years old.
- To determine the prognostic implications of EBV positivity in elderly DLBCL patients.
Main Methods:
- In situ hybridization (ISH) for EBV and immunohistochemistry on 230 DLBCL tumor specimens from patients >50 years old.
- Matched-case control analysis (1:3) comparing EBV-positive and EBV-negative DLBCL in the elderly.
Main Results:
- 16 patients (7.0%) had EBV-positive DLBCL, predominantly non-germinal center B-cell subtype (87.5%) with high Ki67 and CD30 expression.
- EBV-positive elderly DLBCL patients had a median overall survival of 9 months.
- EBV-positive DLBCL showed significantly inferior 3-year progression-free survival (25% vs. 76.7%) and overall survival (25% vs. 77.4%) compared to EBV-negative cases.
Conclusions:
- EBV-positive DLBCL in the elderly is associated with a more aggressive clinical course.
- Patients with EBV-positive DLBCL in this age group experience inferior survival outcomes.
- Further research is needed to elucidate the role of EBV and optimize treatment strategies for this subgroup.
